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Post-transplant T cell deﬁciency (especially in adults) is related to
impaired thymus-dependent lymphopoiesis. However, others and
we have previously found that peripheral T cell apoptosis in recip-
ients of allogeneic bone marrow transplantation (allo BMT) is
increased. We used murine allo BMTmodels to analyze peripheral
T cell apoptosis in three different T cell populations after allo
BMT: T cells derived from (a) donor bone marrow (BM) precur-
sors (de novo generated), (b) infused mature donor T cells in the
allograft (alloreactive and non-alloreactive), and (c) residual host T
cells. In the ﬁrst experiments, we found an increased percentage of
apoptotic (Annexin-V) T cells in both donor derived de novo
generated CD4 and CD8 T cells at day 28 after transplant in
recipients of a T cell depleted (TCD) BMT without GVHD. This
was associated with decreased levels of intracellular Bcl-2 in de
novo generated T cells from both young and old recipients of an
allo TCD BMT. The increased percentages of apoptotic periph-
eral T cells and down regulation of Bcl-2 levels were more prom-
inent in the older recipients. In recipients with GVHD, we found
a severe loss of thymic cellularity, low numbers of BM derived de
novo generated T cells with a high fraction of apoptotic cells and
very low Bcl-2 expression and increased caspase 8 and 9 activation,
Conversely, alloreactive T cells (derived from the infused mature
donor T cells in the allograft) showed upregulation of Fas expres-
sion, higher Bcl-2 levels, less caspase activity and ﬁnally, lower
numbers of apoptotic T cells compared to BM derived T cells. To
determine the effects of Bcl-2 and Fas on T cell reconstitution in
allo BMT recipients, we transplanted donor allografts consisting of
BM from Bcl-2 overexpressing transgenic mice (Bcl-2 Tg) or BM
from Fas-deﬁcient lpr mice with or without wild type congenic T
cells (B6.Ly5.1) into lethally irradiated recipients. Bcl-2 Tg as well
as lpr BM rescued post-transplant thymic cellularity and distribu-
tion and increased CD4 and CD8 T cell numbers in the
periphery, however no change in the fraction of apoptotic cells was
observed. In contrast, post transplant administration of Interleu-
kin-7 and Interleukin-15 reduced the number of apoptotic T cells
in the periphery.
We conclude that peripheral T cell apoptosis is an important
factor in the delay of post transplant T cell reconstitution espe-
cially in older recipients of allo BMT and in recipients with
GVHD.
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Interleukin-15 (IL-15) has been demonstrated to play a critical
role in the proliferation, differentiation, and survival of natural
killer (NK) and CD8 memory T cell populations. Because NK
and memory CD8 T cells recover rapidly following allogeneic
transplantation, we investigated the role of IL-15 as a potential
homeostatic regulator of these two cell types. 39 patients under-
going allogeneic transplant for hematological and non-hematolog-
ical malignancies were assessed for plasma IL-15 levels by ELISA
and IL-15 receptor expression by ﬂow cytometry. The median
plasma IL-15 level from healthy donors was 0.01 pg/ml (range
0.01-.12 pg/ml). Pretreatment median levels of IL-15 in patient
plasma were 0.85 pg/ml (range 0.01-9.7); median NK levels were
105 cells/microL (range 5-573) and CD8 levels were 327 cells/
microL (range 19-1490). IL-15 levels increased through successive
rounds of cytoreductive chemotherapy. Following a high dose
ﬂudarabine/cytoxan conditioning regimen preceding transplant,
IL-15 levels were on average increased by 100 fold from pretreat-
ment levels to a median of 44 pg/ml (range 25-401) (P  0.0001).
NK and CD8 T cell levels at this point were reduced to a median
level of 0 cells/microL (range 0-23). Concurrent with the rapid
recovery of NK (median 223 cells/microL, range 0-816) and
CD8 (median 252 cells/microL, range 11-897) T cells at 2 weeks,
IL-15 levels in the peripheral blood decreased to median levels of
8.7 pg/ml (range 0.9-160). IL-15 levels continued to fall concur-
rent with recovery of cell populations. Each of the 39 patients,
regardless of patient age (adult or pediatric) or graft composition
(CD34 selected versus T-replete) demonstrated the same spike in
plasma IL-15 levels on the day of transplant. Consistent with a key
role for IL-15, we found that the IL-2/IL-15 receptor beta was
expressed at an elevated level on all NK cells and was increased on
CD8 T cells in the post transplant period, whereas the IL-2
receptor alpha chain was expressed at a low level in these popula-
tions. The rise in IL-15 levels may be due to reduced consumption
by therapy diminished populations of lymphocytes or increased
production in response to inﬂammatory cytokines triggered by the
transplant regimen. In either case, these data support the possibil-
ity that IL-15 serves as a critical homeostatic cytokine post trans-
plant, stimulating the initial rapid generation of NK cells and the
expansion of NK and memory CD8 T cell populations.
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T CELL REPERTOIRE COMPLEXITY IS CONSERVED AFTER L-LEUCYL-
L-LEUCINE METHYL ESTER (LLME) TREATMENT OF DONOR LYMPHO-
CYTE INFUSIONS
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Delayed and/or incomplete T cell reconstitution following allo-
geneic hematopoietic stem cell transplantation (HSCT) is a major
risk factor for patient mortality. One approach to rectify this
problem is to administer immunocompetent T cells in the form of
delayed donor lymphocyte infusions (DLI). However, the devel-
opment of graft-versus-host disease (GVHD) is a potential com-
plication of this procedure. We previously found in P3 F1 hap-
loidentical murine models that the ex-vivo treatment of donor
lymphocytes with L-leucyl-L-leucine methyl ester (LLME) can
prevent the onset of GVHD after DLI (BBMT 8:303,2002).
LLME is a lysosomotropic agent that preferentially acts upon cells
containing dipeptidyl peptidase I enzymes (DPPI) in their gran-
ules. The overall effect is to induce cell death of most NK cells,
monocytes, granulocytes, the majority of CD8 T cells, and a
fraction of CD4 T cells. Our previous preclinical studies have
formed the basis of an ongoing phase I clinical trial in which
patients received LLME-treated DLI from their original donor in
an attempt to accelerate T cell reconstitution. In order to under-
stand how this treatment strategy might impact upon the complex-
ity of the DLI T cell repertoire, we used TCR V spectratype
analysis to evaluate the DLI product pre and post-LLME treat-
ment. Peripheral blood T cells obtained from the donors at the
time of DLI, prior to LLME treatment, served as the baseline
spectratype for V complexity. The repertoire complexity of each
LLME-treated DLI product was determined by comparison to its
untreated sample. The results of the spectratype analysis indicated
that the LLME-treated DLI product exhibited CDR3-size distri-
bution complexities similar to its untreated donor sample. In ad-
dition, comparisons of the CD4 T cell repertoire from the donor
before LLME treatment to that of the patient post DLI demon-
strated equal complexity for 92% of the resolvable V families.
Lastly, the in vitro proliferative capacity of an LLME-treated
product in response to third party stimulation in a one-way mixed
lymphocyte reaction was comparable to the untreated product.
Since it appears that LLME treatment of DLI does not adversely
impact the complexity of the T cell repertoire or its functional
capacity, this transplant strategy is likely to afford advantages with
regard to mounting responses to opportunistic infections and pre-
venting leukemic relapse.
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Campath-1H (alemtuzumab) is used during conditioning to
prevent graft-versus-host disease and improve engraftment.
Pharmacokinetic data have shown that a commonly employed
dose of alemtuzumab (20 mg/day x 5, total dose 100 mg) results
in potentially lympholytic alemtuzumab levels for 50 days
post-transplant. Delayed alemtuzumab clearance might con-
tribute to increased incidence of viral infections. We there-
fore studied the effect of a reduced dose of alemtuzumab (20
mg/day x 2, total dose 40 mg) on CMV reactivation. Nine
patients (6 male, 3 female; median age 41 yrs, range 22-55 yrs)
underwent allogeneic stem cell transplantation (7 MUD, 2
MRD) for a variety of hematologic malignancies after condi-
tioning with thiotepa/TBI/alemtuzumab (7 patients) or ﬂudara-
bine/melphalan/alemtuzumab (2 patients). Five patients were at
risk for CMV reactivation (patient or donor CMV seropositive).
Alemtuzumab was administered IV on day -5 and -1 prior to
stem cell infusion. CMV reactivation was checked weekly by
CMV pp65 antigenemia testing in at-risk patients. All patients
received leukocyte depleted blood products (third generation
ﬁlter). All patients engrafted. Four out of ﬁve patients at-risk
(80%) developed CMV reactivation at a median of 28 (range
17-32) days post-transplant. No CMV infection occurred in
low-risk patients (patient and donor both CMV seronegative).
CMV reactivation was treated with IV ganciclovir induction for
a minimum of two weeks, followed by IV or PO (val)ganciclovir
maintenance. Two patients had a febrile illness at the time of
CMV reactivation, however no evidence of CMV disease was
found on imaging studies and/or biopsies. Repeated reactivation
occurred in two patients, and was responsive to retreatment
with ganciclovir or foscarnet with the addition of IVIG. No
patient died from CMV related complications. We conclude
that early CMV reactivation remains a frequently encountered
problem after conditioning regimens containing reduced dose
alemtuzumab. CMV prophylaxis should be considered in at-risk
patients.
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Opportunistic infection, morbidity and mortality are common
following HSC transplantation because of the failure to regen-
erate an adequate immune system. This is due to the severe sex
steroid induced thymic atrophy that occurs with age. Using
surgical or temporary chemical (LHRH/GnRH) castration we
have shown that blocking sex steroids profoundly enhances
thymus function and immune capacity in adult and aged mice.
This involved triggering proliferation of the early thymocyte
precursors, reduction of apoptotic cells and restored thymic
architecture. In addition, in mouse BMT models there was a
signiﬁcant enhancement of BM function and levels therein of
HSC in castrated mice. The HSC were readily incorporated
into the marked regeneration of the thymus. Thus, sex steroid
ablation enhances immune regeneration both at the HSC (BM)
and intrathymic levels. We then examined prostate cancer pa-
tients undergoing routine sex steroid ablation therapy. They
had a signiﬁcant increase in blood T lymphocytes (importantly
CD4 naive TREC) and NK cells, by 4-months post-treat-
ment. This lead to clinical trials using an LHRH agonist to
ablate sex steroids in patients receiving allogeneic or autologous
peripheral blood HSC transplantation (PBST). Compared to
control patients (no LHRH-A treatment), there was ﬁrstly a
signiﬁcantly decreased time to engraftment with both autolo-
gous and allogeneic PBST LHRH-A recipients showing signif-
icant increases in neutrophil counts, total WBC and lymphocyte
counts within the ﬁrst month post-transplant compared to con-
trols. In addition there was a signiﬁcant increase in CD34
stem cell numbers and NK cells in the autologous transplant
recipients who had received the LHRH-A. Importantly the
allogeneic recipients in particular showed an increase in total
and naive (CD45RACD62LCD45RO-; TREC)T cell
numbers in the blood at all time-points post-transplant com-
pared to controls. Patients receiving the LHRH-A treatment
also demonstrated a signiﬁcantly increased in vitro proliferative
responsiveness to TCR stimulation and Tetanus Toxin. These
studies set a fundamentally new approach for the treatment of
many clinically based T-cell disorders.
LEUKEMIA
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BONE MARROW ANGIOGENESIS DECREASES AFTER STEM CELL TRANS-
PLANTATION FOR TREATMENT OF LEUKEMIA
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Background: Bone marrow transplantation is an important
mode of therapy in adult leukemia pateinets. Increased bone
marrow angiogenesis is shown to participate in the progression
of leukemia by direct stimulatory effect of the cytokine secreted
by endothelial cells on the proliferation of leukemia cells, thus
the bone marrow angiogenesis might be a contributory factor in
relapse and also response to therapy. Previous studies have
shown that bone marrow angiogenesis might decrease after stem
cell transplantation in multiple myeloma patients. Aims: To
study whether bone marrow transplantation for the treatment of
leukemia affects the bone marrow vascular density and to clarify
its clinical signiﬁcance. Materials and methods: Pre- and post-
transplant (30 days after transplantation) bone marrow biopsy
samples of 13 patients (3 autologous, 10 allogenic) including 9
AML and 4 ALL patients were evaluated using immunohisto-
chemical staining for vWF. All the vessels in the bone marrow
biopsy core were counted and results were corrected for the
bone marrow biopsy length .The correlation between the de-
gree of decrease in angiogenesis and relapse and Graft-Versus-
Host-Disease was also studied. Results: The bone marrow
angiogenesis was signiﬁcantly decreased after one month of
chemotherapy (Mean pre-transplant vascular number  5.6/mm
/-0.9 SEM, Mean post-transplant vascular number  1.6/mm,
/- 0.26 SEM, P  0.001).There was no correlation between
the degree of angiogenesis and bone marrow cellularity (which
returned to near -normal levels at the time of post-transplant
biopsy).The changes in bone marrow vascular density also did
not correlate with the type of transplant, relapse or the occur-
rence of Graft-Versus-Host-Disease. Discussion: A signiﬁcant
and robust decrease in the bone marrow angiogenesis after stem
cell transplantation for leukemia was shown. This might be a
contributing factor in excellent results of bone marrow trans-
plantation for leukemia by decreasing proliferation stimula-
tory cytokines from the endothelial cells.The lack of correla-
tion between relapse and decrease in bone marrow density
might be attributable to the multifactorial nature of relapse in
leukemia.
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